Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer



(MedPage Today) — WASHINGTON — Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), according to new analyses from…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments